AR and posterior cortical atrophy: In addition, more advanced PCa patients with high risk who received ADT and chemotherapy finally progressed to refractory castration-resistant prostate cancer (CRPC), which was considered to be closely associated with the poor clinical prognostic factor androgen receptor (AR) in PCa [3, 6].